Citations 112
PRODUCT CHARACTERISTICS ASSOCIATED WITH IN VIVO EXPANSION OF ANTI‐CD19 CAR T CELLS IN PATIENTS TREATED WITH AXICABTAGENE CILOLEUCEL (AXI‐CEL)
Neelapu, Sattva S. , Rossi, John M. , Xue, Allen , Better, Marc, Zhang, X., Lekakis, Lazaros J. , Jacobson, Caron A. , Braunschweig, Ira , Oluwole, Olalekan O. , Timmerman, John M. , Navale, Lynn, Go, William Y., Wiezorek, Jeff, Bot, Adrian , Locke, Frederick L. , Ghobadi, Armin , Miklos, David B. , Siddiqi, Tanya , Lin, Yi , Reagan, Patrick Michael , Oluwole, Olalekan O
Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 262-263
AXICABTAGENE CILOLEUCEL (AXI‐CEL; KTE‐C19) IN PATIENTS WITH REFRACTORY AGGRESSIVE NON‐HODGKIN LYMPHOMAS (NHL): PRIMARY RESULTS OF THE PIVOTAL TRIAL ZUMA‐1
Neelapu, Sattva S. , Lekakis, Lazaros J. , Jacobson, Caron A. , Braunschweig, Ira , Timmerman, John M. , Navale, Lynn, Jiang, Yizhou , Aycock, Jeff, Elias, Meg , Wiezorek, Jeff, Go, William Y., Locke, Frederick L. , Bartlett, Nancy L. , Miklos, David B. , Oluwole, Olalekan O. , Siddiqi, Tanya , Lin, Yi , Reagan, Patrick Michael
Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 28-28